JP2014240404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014240404A5 JP2014240404A5 JP2014154372A JP2014154372A JP2014240404A5 JP 2014240404 A5 JP2014240404 A5 JP 2014240404A5 JP 2014154372 A JP2014154372 A JP 2014154372A JP 2014154372 A JP2014154372 A JP 2014154372A JP 2014240404 A5 JP2014240404 A5 JP 2014240404A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- regulatory
- cell epitope
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89834707P | 2007-01-30 | 2007-01-30 | |
| US60/898,347 | 2007-01-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011247226A Division JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064298A Division JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014240404A JP2014240404A (ja) | 2014-12-25 |
| JP2014240404A5 true JP2014240404A5 (enExample) | 2015-02-12 |
| JP6121369B2 JP6121369B2 (ja) | 2017-04-26 |
Family
ID=39674696
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548278A Expired - Fee Related JP4866467B2 (ja) | 2007-01-30 | 2008-01-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2011247226A Expired - Fee Related JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2014154372A Expired - Fee Related JP6121369B2 (ja) | 2007-01-30 | 2014-07-30 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2017064298A Expired - Fee Related JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2019008352A Pending JP2019089793A (ja) | 2007-01-30 | 2019-01-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021011596A Withdrawn JP2021073255A (ja) | 2007-01-30 | 2021-01-28 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072446A Pending JP2021107443A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072455A Pending JP2021107444A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2022155804A Pending JP2022177270A (ja) | 2007-01-30 | 2022-09-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2024033497A Pending JP2024059975A (ja) | 2007-01-30 | 2024-03-06 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548278A Expired - Fee Related JP4866467B2 (ja) | 2007-01-30 | 2008-01-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2011247226A Expired - Fee Related JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064298A Expired - Fee Related JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2019008352A Pending JP2019089793A (ja) | 2007-01-30 | 2019-01-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021011596A Withdrawn JP2021073255A (ja) | 2007-01-30 | 2021-01-28 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072446A Pending JP2021107443A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072455A Pending JP2021107444A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2022155804A Pending JP2022177270A (ja) | 2007-01-30 | 2022-09-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2024033497A Pending JP2024059975A (ja) | 2007-01-30 | 2024-03-06 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (18) | US7884184B2 (enExample) |
| EP (13) | EP2423219B1 (enExample) |
| JP (10) | JP4866467B2 (enExample) |
| KR (3) | KR20100014871A (enExample) |
| CN (4) | CN107011431B (enExample) |
| AT (1) | ATE525392T1 (enExample) |
| AU (1) | AU2008211227B2 (enExample) |
| CA (6) | CA3161849A1 (enExample) |
| IL (3) | IL200129A (enExample) |
| MX (3) | MX347197B (enExample) |
| WO (1) | WO2008094538A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3161849A1 (en) | 2007-01-30 | 2008-08-07 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| DE102007030904A1 (de) * | 2007-07-03 | 2009-02-05 | Pharis Biotec Gmbh | Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| WO2013088194A1 (en) * | 2011-12-13 | 2013-06-20 | Centre National De La Recherche Scientifique | Modified peptides and their use for treating autoimmune diseases |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CN106132432A (zh) * | 2013-12-06 | 2016-11-16 | 博德研究所 | 用于瘤形成疫苗的配制品 |
| RU2021109685A (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
| US10213482B2 (en) | 2014-12-12 | 2019-02-26 | Immupharma France Sa | Methods of treating chronic inflammatory diseases |
| EP3253419A1 (en) | 2015-02-02 | 2017-12-13 | The University of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| WO2016178811A1 (en) * | 2015-05-04 | 2016-11-10 | Epivax, Inc. | Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence |
| CN107921097A (zh) | 2015-05-04 | 2018-04-17 | 埃皮瓦克斯公司 | 流感a/shanghai/2/2013 h7序列的改性h7血凝素糖蛋白 |
| PT3377103T (pt) | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
| PL238939B1 (pl) * | 2016-11-02 | 2021-10-18 | Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu | Peptyd immunosupresyjny i jego zastosowania |
| JP7274472B2 (ja) * | 2017-10-05 | 2023-05-16 | エピバックス、インコーポレイテッド | 制御性ｔ細胞エピトープ |
| EP3622962A1 (en) * | 2018-09-14 | 2020-03-18 | advanceCOR GmbH | Short cyclic peptides for the treatment of graves' disease |
| EP3963335B1 (en) * | 2019-05-03 | 2024-08-21 | Epivax Therapeutics, Inc. | Neoantigens in cancer |
| CA3172976A1 (en) * | 2020-03-27 | 2021-09-30 | Epivax, Inc. | Regulatory t cell epitopes |
| EP4126927A1 (en) * | 2020-03-27 | 2023-02-08 | Biotest AG | Protein comprising at least one regulatory t cell activating epitope |
| CN111856020B (zh) * | 2020-06-19 | 2022-09-27 | 南方医科大学南方医院 | 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用 |
| EP4196232A2 (en) * | 2020-08-13 | 2023-06-21 | Epivax, Inc. | Regulatory t cell epitopes |
| AU2021350011A1 (en) * | 2020-09-25 | 2023-05-11 | Epivax, Inc. | Retro-inverso regulatory t cell epitopes |
| JP2024524730A (ja) * | 2021-07-16 | 2024-07-05 | デベヴェ・テクノロジーズ | 対象におけるカシュー耐性を増大させるための免疫治療法 |
| CN121532211A (zh) | 2023-05-19 | 2026-02-13 | 努玛治疗有限公司 | 具有降低的免疫原性的抗体可变结构域及抗体 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| GB8725529D0 (en) † | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| FR2686899B1 (fr) † | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5817308A (en) * | 1994-02-14 | 1998-10-06 | University Of Rochester | Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| EP0888125B1 (en) | 1996-03-20 | 2004-05-26 | Immunomedics, Inc. | GLYCOSYLATED IgG ANTIBODIES |
| US6090381A (en) * | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| JP2002505574A (ja) * | 1997-04-30 | 2002-02-19 | エンゾン，インコーポレイテッド | ポリアルキレンオキシド修飾された単鎖ポリペプチド |
| US6953675B2 (en) | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2003501043A (ja) | 1999-05-28 | 2003-01-14 | ターゲティッド ジェネティクス コーポレイション | 腫瘍壊死因子（ｔｎｆ）関連障害において、ｔｎｆのレベルを低下させるための方法および組成物 |
| US6445840B1 (en) | 1999-05-28 | 2002-09-03 | Omm, Inc. | Micromachined optical switching devices |
| JP2003530838A (ja) † | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| JP2004502946A (ja) † | 2000-07-10 | 2004-01-29 | ゼンコー | 改変された免疫原性を有するタンパク質ライブラリーを設計するためのタンパク質設計オートメーション |
| CA2441095A1 (en) * | 2001-03-15 | 2002-09-26 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified interferon beta with reduced immunogenicity |
| US6992174B2 (en) † | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| MXPA04004417A (es) * | 2001-11-12 | 2004-08-11 | Merck Patent Gmbh | Anticuerpo anti-tnf alfa modificado. |
| EP1453539B1 (en) † | 2001-12-05 | 2008-11-19 | Circassia Limited | Immunotherapeutic methods and systems |
| ES2425738T3 (es) † | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| AU2002364587A1 (en) † | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| KR20110014661A (ko) † | 2002-02-07 | 2011-02-11 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민-융합 쿠니츠 도메인 펩타이드 |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| DK1532262T3 (da) | 2002-05-24 | 2013-09-16 | Medtronic Inc | Peptidamideringsfremgangsmåde |
| WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| CN1511958A (zh) * | 2002-12-31 | 2004-07-14 | 王小宁 | 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用 |
| EP1594530A4 (en) † | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| NZ548821A (en) | 2004-02-06 | 2009-12-24 | Univ Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
| EP1729795B1 (en) † | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MXPA06010716A (es) * | 2004-03-19 | 2007-02-21 | Merck Patent Gmbh | Proteinas bouganin modificadas, citotoxinas y metodos y usos de las mismas. |
| RU2386638C2 (ru) * | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| AU2005271452B2 (en) | 2004-08-03 | 2011-11-03 | Vtv Therapeutics Llc | RAGE fusion proteins and methods of use |
| CN101010430A (zh) | 2004-08-03 | 2007-08-01 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| US7488804B2 (en) † | 2005-02-02 | 2009-02-10 | The Regents Of The University Of California | Modified fusion molecules for treatment of allergic disease |
| JP2008528668A (ja) * | 2005-02-03 | 2008-07-31 | アンチトープ リミテッド | ヒト抗体及びタンパク質 |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| AU2006280312A1 (en) † | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN100349921C (zh) * | 2005-11-17 | 2007-11-21 | 中国人民解放军第四军医大学 | 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备 |
| AU2006330922B2 (en) * | 2005-12-20 | 2012-07-26 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
| GEP20135917B (en) * | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| GB0605735D0 (en) | 2006-03-22 | 2006-05-03 | Immunobiology Ltd | Composition and method for mediating an immune response |
| BRPI0712383A2 (pt) † | 2006-06-07 | 2012-07-10 | Human Genome Sciences Inc | proteìnas de fusão da albumina |
| AT503861B1 (de) † | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| CA3161849A1 (en) * | 2007-01-30 | 2008-08-07 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| BRPI0812465A2 (pt) | 2007-06-08 | 2014-12-02 | Dow Global Technologies Inc | Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1 |
-
2008
- 2008-01-29 CA CA3161849A patent/CA3161849A1/en active Pending
- 2008-01-29 CN CN201610958012.4A patent/CN107011431B/zh not_active Expired - Fee Related
- 2008-01-29 CA CA2677073A patent/CA2677073C/en active Active
- 2008-01-29 EP EP20110177609 patent/EP2423219B1/en not_active Not-in-force
- 2008-01-29 MX MX2015014429A patent/MX347197B/es unknown
- 2008-01-29 US US12/021,832 patent/US7884184B2/en active Active
- 2008-01-29 JP JP2009548278A patent/JP4866467B2/ja not_active Expired - Fee Related
- 2008-01-29 KR KR1020097017996A patent/KR20100014871A/ko not_active Ceased
- 2008-01-29 EP EP12153171A patent/EP2450369A1/en not_active Withdrawn
- 2008-01-29 CA CA3034396A patent/CA3034396C/en active Active
- 2008-01-29 CA CA3001783A patent/CA3001783C/en active Active
- 2008-01-29 EP EP12153173A patent/EP2450370A1/en not_active Withdrawn
- 2008-01-29 EP EP12153170A patent/EP2450368A1/en not_active Withdrawn
- 2008-01-29 EP EP20110177625 patent/EP2423220B1/en not_active Not-in-force
- 2008-01-29 AU AU2008211227A patent/AU2008211227B2/en not_active Ceased
- 2008-01-29 EP EP20110177630 patent/EP2423221B1/en not_active Not-in-force
- 2008-01-29 EP EP20120153177 patent/EP2450372B1/en not_active Not-in-force
- 2008-01-29 KR KR1020177008095A patent/KR20170037677A/ko not_active Ceased
- 2008-01-29 MX MX2009008230A patent/MX2009008230A/es active IP Right Grant
- 2008-01-29 WO PCT/US2008/001148 patent/WO2008094538A2/en not_active Ceased
- 2008-01-29 KR KR1020147024226A patent/KR101722305B1/ko not_active Expired - Fee Related
- 2008-01-29 CA CA2963138A patent/CA2963138C/en active Active
- 2008-01-29 EP EP15153373.4A patent/EP2896630B1/en not_active Not-in-force
- 2008-01-29 EP EP08713321.1A patent/EP2125883B2/en not_active Not-in-force
- 2008-01-29 AT AT08713321T patent/ATE525392T1/de not_active IP Right Cessation
- 2008-01-29 CN CN201310685046.7A patent/CN103755789B/zh not_active Expired - Fee Related
- 2008-01-29 CN CN200880011016.5A patent/CN101687912B/zh not_active Expired - Fee Related
- 2008-01-29 CN CN202011190692.2A patent/CN112279911A/zh active Pending
- 2008-01-29 EP EP12153166A patent/EP2450367A1/en not_active Withdrawn
- 2008-01-29 EP EP11177634.0A patent/EP2423222B2/en not_active Not-in-force
- 2008-01-29 EP EP12153164A patent/EP2450366A1/en not_active Withdrawn
- 2008-01-29 EP EP20120153174 patent/EP2450371B1/en not_active Not-in-force
- 2008-01-29 CA CA2915168A patent/CA2915168C/en active Active
-
2009
- 2009-07-28 IL IL200129A patent/IL200129A/en active IP Right Grant
- 2009-07-30 MX MX2018015933A patent/MX2018015933A/es unknown
-
2010
- 2010-12-29 US US12/981,098 patent/US20110182921A1/en not_active Abandoned
-
2011
- 2011-11-11 JP JP2011247226A patent/JP5643739B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-30 JP JP2014154372A patent/JP6121369B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,693 patent/US10213496B2/en active Active
-
2016
- 2016-05-04 IL IL245478A patent/IL245478B/en active IP Right Grant
-
2017
- 2017-03-29 JP JP2017064298A patent/JP6472476B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-22 US US16/015,796 patent/US10925939B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,837 patent/US11045531B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,822 patent/US11045529B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,784 patent/US10751397B2/en active Active
- 2018-06-22 US US16/015,814 patent/US11045528B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,828 patent/US11045530B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,802 patent/US10925940B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,674 patent/US10925941B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,671 patent/US11045532B2/en not_active Expired - Fee Related
-
2019
- 2019-01-22 JP JP2019008352A patent/JP2019089793A/ja active Pending
- 2019-03-04 US US16/291,372 patent/US10925942B2/en not_active Expired - Fee Related
- 2019-03-04 US US16/291,658 patent/US10980867B2/en not_active Expired - Fee Related
- 2019-06-10 IL IL267186A patent/IL267186B/en active IP Right Grant
- 2019-08-02 US US16/530,104 patent/US20190351036A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021011596A patent/JP2021073255A/ja not_active Withdrawn
- 2021-04-21 US US17/236,463 patent/US11844826B2/en active Active
- 2021-04-21 US US17/236,534 patent/US12016909B2/en active Active
- 2021-04-22 JP JP2021072446A patent/JP2021107443A/ja active Pending
- 2021-04-22 JP JP2021072455A patent/JP2021107444A/ja active Pending
-
2022
- 2022-01-14 US US17/576,321 patent/US20220211827A1/en not_active Abandoned
- 2022-09-29 JP JP2022155804A patent/JP2022177270A/ja active Pending
-
2024
- 2024-03-06 JP JP2024033497A patent/JP2024059975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014240404A5 (enExample) | ||
| JP2017165733A5 (enExample) | ||
| AR127116A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| WO2015142314A8 (en) | Compositions and methods for immunotherapy | |
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| JP2015131795A5 (enExample) | ||
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2010516290A5 (enExample) | ||
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| PE20181490A1 (es) | Tratamientos contra el cancer de utero | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| MX392416B (es) | Métodos y composiciones para terapia celular adoptiva. | |
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| EP3456339A3 (en) | Novel immunotherapy against several tumors, such as lung cancer including nsclc | |
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| WO2011113819A3 (en) | Diagnosis and treatment of cancer based on avl9 | |
| WO2016173605A8 (en) | Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof | |
| JP2018023397A5 (enExample) | ||
| JP2017501211A5 (enExample) | ||
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| MX2020003129A (es) | Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva. |